Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;14(4):3279-3287.
doi: 10.3892/etm.2017.4863. Epub 2017 Aug 2.

A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

Huibiao Quan  1 , Huachuan Zhang  1 , Weiping Wei  1 , Tuanyu Fang  1 , Daoxiong Chen  1 , Kaining Chen  1
Affiliations

A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

Huibiao Quan et al. Exp Ther Med. 2017 Oct.

Abstract

The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3-0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A). In groups A and B a significant decrease and increase, respectively, in glycated hemoglobin (HbAlc) and body mass index (BMI) was noted during Phase I. A 3.2±0.4-kg decrease in body weight in group A and a 2.6±0.3-kg increase in group B was observed. In Phase II, HbAlc was significantly increased in both groups (P<0.05). In Phase III, the BMI was increased in group A and reduced in group B (P<0.05). There was a 3.8±0.4-kg weight decrease in group B and 4.2±0.5-kg increase in group A (P<0.05). The combination of exenatide and MET promoted weight loss, glycemic control, β-cell function index, C peptide and adiponectin levels. These results suggested that the combination of exenatide and MET is better than the combination of BIA and MET for the therapy of overweight or obese patients newly diagnosed with T2DM.

Keywords: biphasic insulin aspart; combination therapy; exenatide; metformin; obesity; overweight; type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the study. Group A (n=100; 5 µg exenatide +0.5 g MET twice daily for 4 weeks, then 10 µg exenatide +0.5 g MET twice daily for 8 weeks; then only 0.5 g MET twice daily for 12 weeks; thereafter, 0.3–0.4 U/kg/day BIA30 +0.5 g MET twice daily for 12 weeks) and Group B (n=100; 0.3–0.4 U/kg/day BIA30 +0.5 µg MET twice daily for 12 weeks; then only 0.5 g MET twice daily for 12 weeks; thereafter, 5 µg exenatide +0.5 g MET twice daily for 12 weeks). MET, metformin, BIA30, biphasic insulin aspart 30.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lewis CP, Newell JN. Patients' perspectives of care for type 2 diabetes in Bangladesh-a qualitative study. BMC Public Health. 2014;14:737. doi: 10.1186/1471-2458-14-737. - DOI - PMC - PubMed
    1. Wang Y, Zhao L, Huang Q, Peng Y. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists. J Diabetes. 2014;6:164–166. doi: 10.1111/1753-0407.12077. - DOI - PubMed
    1. Umpierrez GE, Meneghini L. Reshaping diabetes care: The fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. Endocr Pract. 2013;19:718–728. doi: 10.4158/EP12292.RA. - DOI - PubMed
    1. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742. doi: 10.1038/nrendo.2012.140. - DOI - PubMed
    1. Knudsen Bjerre L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–1486. doi: 10.1210/en.2009-1272. - DOI - PubMed